Mammographic breast density during hormone replacement therapy: Differences according to treatment


      Objective: Our purpose was to investigate the effects of various hormone replacement regimens on mammographic breast density. Study Design: Mammographic density was recorded in women participating in a population-based screening program. All women were nonusers of hormone replacement therapy at first mammogram and thereafter reported continuous use of the same treatment: estrogen alone (n = 50) or estrogen in cyclic (n = 75) or continuous (n = 50) combination with progestogen. Mammographic density was quantified according to the Wolfe classification. Results: An increase in mammographic density was much more common among women receiving continuous combination hormone replacement therapy (52%) than among those receiving cyclic (13%) and estrogen-only (18%) treatment. The increase in density was apparent already at first visit after the start of hormone replacement therapy. There was little change in mammographic status during long-term follow-up. Conclusion: Regimens of hormone replacement therapy were shown to have different effects on the normal breast. There is an urgent need to clarify the biologic nature and significance of a change in mammographic density during treatment and, in particular, its relation to symptoms and breast cancer risk. (Am J Obstet Gynecol 1999;181:348-52.)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Practical HRT. Medicom, Bussum, The Netherlands1995
        • Beral V
        • Bull D
        • Doll R
        • Key T
        • Peto R
        • Reeves G
        • Collaborative Group on Hormonal Factors in Breast Cancer
        Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.
        Lancet. 1997; 350: 1047-1059
        • Nyström L
        • Rutqvist LE
        • Wall S
        • Lindgren A
        • Lindqvist M
        • Rydén S
        • et al.
        Breast cancer screening with mammography: overview of Swedish randomized trials.
        Lancet. 1993; 341: 973-978
        • Kaufman Z
        • Garstin WIH
        • Hayes R
        • Michell MJ
        • Baum M
        The mammographic parenchymal patterns of women on hormonal replacement therapy.
        Clin Radiol. 1991; 43: 389-392
        • Leung W
        • Goldberg F
        • Zee B
        • Sterns E
        Mammographic density in women on postmenopausal hormone replacement therapy.
        Surgery. 1997; 122: 669-674
        • Persson I
        • Thurfjell E
        • Holmberg L
        Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density.
        J Clin Oncol. 1997; 15: 3201-3207
        • Laya MB
        • Larson EB
        • Taplin SH
        • White E
        Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography.
        J Natl Cancer Inst. 1996; 88: 643-649
        • Bland KI
        • Buchanan JB
        • Weisberg BF
        • Hagan TA
        • Gray LA
        The effects of exogenous estrogen replacement therapy of the breast: breast cancer risk and mammographic parenchymal patterns.
        Cancer. 1980; 45: 3027-3033
        • Buchanan JB
        • Weisberg BF
        • Sandoz JP
        • Gray LA
        • Bland KI
        Selected prognostic variables for mammographic parenchymal patterns.
        Cancer. 1981; 47: 2135-2137
        • Laya MB
        • Gallagher JC
        • Schreiman JS
        • Larson EB
        • Watson P
        • Weinstein L
        Effects of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern.
        Radiology. 1995; 196: 433-437
        • Marugg RC
        • van der Mooren MJ
        • Hendriks JH
        • Rolland R
        • Ruijs SH
        Mammographic changes in postmenopausal women on hormonal replacement therapy.
        Eur Radiol. 1997; 7: 749-755
        • Wolfe JN
        Breast patterns as an index of risk for developing breast cancer.
        AJR Am J Roentgenol. 1976; 126: 1130-1139
        • Wolfe JN
        Risk for breast cancer development determined by mammographic parenchymal pattern.
        Cancer. 1976; 37: 2486-2492
        • Stomper PC
        • Van Voorhis BJ
        • Ravnikar VA
        • Meyer JE
        Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study.
        Radiology. 1990; 174: 498-590
        • Cyrlak D
        • Wong CH
        Mammographic changes in postmenopausal women undergoing hormonal replacement therapy.
        AJR Am J Roentgenol. 1993; 161: 1177-1183
        • Söderqvist G
        • Isaksson E
        • von Schoultz B
        • Carlström K
        • Tani E
        • Skoog L
        Proliferation of breast epithelial cells in healthy women during the menstrual cycle.
        Am J Obstet Gynecol. 1997; 176: 123-128
        • Cline JM
        • Söderqvist G
        • von Schoultz B
        • Skoog L
        • von Schoultz E
        Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques.
        Am J Obstet Gynecol. 1996; 174: 93-100
        • Reid SE
        • Murthy MS
        • Kaufman M
        • Scanlon EF
        Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer.
        Br J Surg. 1996; 83: 1037-1046
        • Bonney RC
        The role of progestins and antiprogestins in the treatment of breast cancer.
        Endocrinol Rel Cancer. 1996; 3: 113-125
        • Miller WR
        • Langdon SP
        Steroid hormones and cancer. II. Lessons from experimental systems.
        Eur J Surg Oncol. 1997; 23: 163-183
        • Wren BG
        • Eden JA
        Do progestogens reduce the risk of breast cancer? a review of the evidence.
        Menopause. 1996; 3: 4-12
        • Pike MC
        • Spicer DV
        • Dahmoush L
        • Press MF
        Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.
        Epidemiol Rev. 1993; 168: 1473-1480
        • Byrne C
        • Schairer C
        • Wolfe J
        • Parekh N
        • Salane M
        • Brinton LA
        • et al.
        Mammographic features and breast cancer risk: effects with time, age, and menopause status.
        J Natl Cancer Inst. 1995; 87: 1622-1629
        • Hill P
        Breast density and cancer.
        J Natl Cancer Inst. 1997; 89: 1721-1722
        • Spicer DV
        • Ursin G
        • Parisky YR
        • Pearce JG
        • Shoupe D
        • Pike A
        • et al.
        Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
        J Natl Cancer Inst. 1994; 86: 431-436
        • McNicholas MM
        • Heneghan JP
        • Milner MH
        • Tunney T
        • Hourihane JB
        • MacErlaine DP
        Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study.
        AJR Am J Roentgenol. 1994; 163: 311-315